Masimo Co. (NASDAQ:MASI) Short Interest Update

Masimo Co. (NASDAQ:MASI) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 2,740,000 shares, a decrease of 20.6% from the December 15th total of 3,450,000 shares. Based on an average daily trading volume, of 561,600 shares, the short-interest ratio is presently 4.9 days. Currently, 5.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Masimo

Several institutional investors have recently modified their holdings of MASI. NBC Securities Inc. increased its position in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the period. MML Investors Services LLC increased its holdings in shares of Masimo by 4.9% during the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after buying an additional 96 shares during the last quarter. Assetmark Inc. grew its position in Masimo by 12.7% during the third quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock valued at $158,000 after acquiring an additional 133 shares during the period. Nordea Investment Management AB grew its holdings in shares of Masimo by 0.7% during the 4th quarter. Nordea Investment Management AB now owns 19,182 shares of the medical equipment provider’s stock worth $3,206,000 after purchasing an additional 142 shares during the period. Finally, Sofinnova Investments Inc. increased its position in shares of Masimo by 0.8% in the second quarter. Sofinnova Investments Inc. now owns 20,161 shares of the medical equipment provider’s stock worth $2,539,000 after acquiring an additional 161 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MASI shares. BTIG Research upped their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company upped their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Piper Sandler upped their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.

Masimo Trading Up 1.3 %

NASDAQ MASI traded up $2.17 during trading hours on Wednesday, reaching $168.26. The company had a trading volume of 30,789 shares, compared to its average volume of 406,617. The stock has a 50-day moving average of $168.77 and a 200 day moving average of $139.31. The stock has a market capitalization of $9.01 billion, a P/E ratio of 116.04 and a beta of 1.01. Masimo has a 1-year low of $101.61 and a 1-year high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same quarter in the prior year, the company earned $0.63 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, research analysts anticipate that Masimo will post 4.03 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.